Literature DB >> 20965493

Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.

Ie-Ming Shih1, Li Chen, Chen C Wang, Jinghua Gu, Ben Davidson, Leslie Cope, Robert J Kurman, Jianhua Xuan, Tian-Li Wang.   

Abstract

OBJECTIVE: The purpose of this study was to analyze DNA methylation profiles among different types of ovarian serous neoplasm, which is a task that has not been performed. STUDY
DESIGN: The Illumina beads array (Illumina Inc, San Diego, CA) was used to profile DNA methylation in enriched tumor cells that had been isolated from 75 benign and malignant serous tumor tissues and 6 tumor-associated stromal cell cultures.
RESULTS: We found significantly fewer hypermethylated genes in high-grade serous carcinomas than in low-grade serous carcinoma and borderline tumors, which in turn had fewer hypermethylated genes than serous cystadenoma. Unsupervised analysis identified that serous cystadenoma, serous borderline tumor, and low-grade serous carcinomas tightly clustered together and were clearly different from high-grade serous carcinomas. We also performed supervised analysis to identify differentially methylated genes that may contribute to group separation.
CONCLUSION: The findings support the view that low-grade and high-grade serous carcinomas are distinctly different with low-grade, but not high-grade, serous carcinomas that are related to serous borderline tumor and cystadenoma.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20965493      PMCID: PMC2993872          DOI: 10.1016/j.ajog.2010.08.003

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  33 in total

Review 1.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

2.  Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor.

Authors:  Yuji Satoh; Tetsuji Nakagawachi; Hisaya Nakadate; Yasuhiko Kaneko; Zenjiro Masaki; Tsunehiro Mukai; Hidenobu Soejima
Journal:  J Biochem       Date:  2003-03       Impact factor: 3.387

3.  DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.

Authors:  Kuan-Ting Kuo; Tsui-Lien Mao; Xu Chen; Yuanjian Feng; Kentaro Nakayama; Yue Wang; Ruth Glas; M Joe Ma; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

4.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Authors:  Gad Singer; Robert Oldt; Yoram Cohen; Brant G Wang; David Sidransky; Robert J Kurman; Ie-Ming Shih
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

Review 6.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

7.  The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer.

Authors:  T Yoshida; S Tanaka; A Mogi; Y Shitara; H Kuwano
Journal:  Ann Oncol       Date:  2004-02       Impact factor: 32.976

8.  Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.

Authors:  Inmaculada Ibanez de Caceres; Cristina Battagli; Manel Esteller; James G Herman; Essel Dulaimi; Mitchell I Edelson; Cynthia Bergman; Hormoz Ehya; Burton L Eisenberg; Paul Cairns
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

9.  Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.

Authors:  Chung-Liang Ho; Robert J Kurman; Reiko Dehari; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

10.  OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.

Authors:  Grant C Sellar; Karen P Watt; Genevieve J Rabiasz; Euan A Stronach; Li Li; Eric P Miller; Charles E Massie; Jayne Miller; Bruno Contreras-Moreira; Diane Scott; Iain Brown; Alastair R Williams; Paul A Bates; John F Smyth; Hani Gabra
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

View more
  32 in total

1.  The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

Authors:  Erin R King; Zhifei Zu; Yvonne T M Tsang; Michael T Deavers; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Gynecol Oncol       Date:  2011-07-02       Impact factor: 5.482

Review 2.  Epigenetics in ovarian cancer.

Authors:  Yanina Natanzon; Ellen L Goode; Julie M Cunningham
Journal:  Semin Cancer Biol       Date:  2017-08-03       Impact factor: 15.707

3.  BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Authors:  Felix Zeppernick; Laura Ardighieri; Charlotte G Hannibal; Russell Vang; Jette Junge; Susanne K Kjaer; Rugang Zhang; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

4.  Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.

Authors:  Daina Skiriutė; Paulina Vaitkienė; Virginija Ašmonienė; Giedrius Steponaitis; Vytenis Pranas Deltuva; Arimantas Tamašauskas
Journal:  J Neurooncol       Date:  2013-04-28       Impact factor: 4.130

5.  Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients.

Authors:  Verena Kirn; Rong Shi; Sabine Heublein; Julia Knabl; Margit Guenthner-Biller; Ulrich Andergassen; Claudius Fridrich; Wolfram Malter; Jan Harder; Klaus Friese; Doris Mayr; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-08       Impact factor: 4.553

Review 6.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

7.  The green tea polyphenol EGCG alleviates maternal diabetes-induced neural tube defects by inhibiting DNA hypermethylation.

Authors:  Jianxiang Zhong; Cheng Xu; E Albert Reece; Peixin Yang
Journal:  Am J Obstet Gynecol       Date:  2016-03-12       Impact factor: 8.661

8.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

9.  Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.

Authors:  Chi-An Chen; Ying-Cheng Chiang; Ming-Cheng Chang; Yu-Hao Hu; San-Lin You; Yeu-Yao Kevin Cheng; Cheng-Yang Chou; Wen-Fang Cheng
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

Review 10.  DNA methylation changes in epithelial ovarian cancer histotypes.

Authors:  Madalene A Earp; Julie M Cunningham
Journal:  Genomics       Date:  2015-09-10       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.